Traws Pharma, INC Form 4 insider transactions

Charles David Pauza, Chief Science Officer Virology of Traws Pharma, Inc., received 97,000 shares of common stock on July 9, 2026.

Werner Cautreels, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

Nikolay Savchuk, Chief Operating Officer and a Director of Traws Pharma, Inc., received 93,000 shares of common stock on July 9, 2026.

Jack E Stover, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

Iain D. Dukes, Chief Executive Officer and a Director of Traws Pharma, Inc., received 274,000 shares of common stock on July 9, 2026.

Robert Redfield, Chief Medical Officer of Traws Pharma, Inc., received 84,000 shares of common stock on July 9, 2026.

Charles Nolan Parker, Chief Financial Officer of Traws Pharma, Inc., received 90,000 shares of common stock on July 9, 2026.

Mary Teresa Shoemaker, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

Trafford Clarke, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

John Harold Leaman, a Director of Traws Pharma, Inc., received 14,150 shares of common stock on July 9, 2026.

OrbiMed Advisors LLC has significantly expanded its position in Traws Pharma, Inc. through a private placement involving common stock and nearly 3 million warrants.

Traws Pharma's Chief Financial Officer, Charles Nolan Parker, has acquired a significant number of stock options and restricted stock units.

Traws Pharma, Inc. Director John Harold Leaman received awards of 4,058 restricted stock units and options to purchase 16,234 shares of common stock.

Traws Pharma Director Trafford Clarke was granted 6,157 restricted stock units and options to purchase 24,629 shares of common stock.

Traws Pharma Director Werner Cautreels received awards of 4,874 restricted stock units and 19,496 stock options, increasing his beneficial ownership.

Traws Pharma, Inc. Director Mary Teresa Shoemaker received an award of 6,157 restricted stock units and 24,629 stock options.

Traws Pharma director Jack E. Stover received an award of 6,157 restricted stock units and 24,629 stock options on December 12, 2025.

Traws Pharma, Inc. CEO Iain D. Dukes received grants of restricted stock units and stock options, aligning executive incentives with shareholder value.

Traws Pharma's Chief Science Officer, Charles David Pauza, was granted 18,471 restricted stock units and 73,886 stock options as part of his compensation.

Traws Pharma's Chief Medical Officer, Robert Redfield, acquired 16,419 restricted stock units and 65,676 stock options, increasing his beneficial ownership.

Traws Pharma's Chief Operating Officer, Nikolay Savchuk, was granted 16,419 restricted stock units and 65,676 stock options.

Traws Pharma, Inc. Director John Harold Leaman was granted 12,770 stock options with an exercise price of $2.31, vesting over three years.

Traws Pharma's Chief Operating Officer and Director, Nikolay Savchuk, acquired 22,435 stock options with an exercise price of $3.01, vesting in one year.

Traws Pharma's Chief Medical Officer, Robert Redfield, was granted 32,406 stock options with an exercise price of $3.01, vesting 100% on the first anniversary of the grant date.

Traws Pharma's Chief Science Officer, Charles David Pauza, acquired 32,406 stock options with an exercise price of $3.01, vesting on the first anniversary of the grant date.

Traws Pharma, Inc. CEO Iain D. Dukes was granted 64,839 stock options with an exercise price of $3.01, vesting in one year.

Traws Pharma, Inc. Director Werner Cautreels was granted 11,530 stock options with an exercise price of $3.01, vesting fully on October 12, 2026.

Traws Pharma Director Jack E. Stover acquired 11,530 stock options with an exercise price of $3.01, vesting in one year.

Traws Pharma Director Trafford Clarke acquired 11,530 stock options with an exercise price of $3.01, vesting fully on October 12, 2026.

Traws Pharma, Inc. Director Mary Teresa Shoemaker was granted 11,530 stock options with an exercise price of $3.01, vesting 100% on the first anniversary of the grant date.